JP2003512443A - タキサンをヒト患者に経口投与するための方法及び組成物 - Google Patents

タキサンをヒト患者に経口投与するための方法及び組成物

Info

Publication number
JP2003512443A
JP2003512443A JP2001532859A JP2001532859A JP2003512443A JP 2003512443 A JP2003512443 A JP 2003512443A JP 2001532859 A JP2001532859 A JP 2001532859A JP 2001532859 A JP2001532859 A JP 2001532859A JP 2003512443 A JP2003512443 A JP 2003512443A
Authority
JP
Japan
Prior art keywords
paclitaxel
taxane
formulation
administration
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001532859A
Other languages
English (en)
Japanese (ja)
Inventor
ブロードアー，サミュエル
ダッチン，ケニス
シーリム，セイミ
Original Assignee
ベーカー ノートン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーカー ノートン ファーマシューティカルズ インコーポレイテッド filed Critical ベーカー ノートン ファーマシューティカルズ インコーポレイテッド
Publication of JP2003512443A publication Critical patent/JP2003512443A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001532859A 1999-10-27 2000-10-27 タキサンをヒト患者に経口投与するための方法及び組成物 Pending JP2003512443A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16231099P 1999-10-27 1999-10-27
US60/162,310 1999-10-27
PCT/US2000/029633 WO2001030448A1 (en) 1999-10-27 2000-10-27 Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number Publication Date
JP2003512443A true JP2003512443A (ja) 2003-04-02

Family

ID=22585092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001532859A Pending JP2003512443A (ja) 1999-10-27 2000-10-27 タキサンをヒト患者に経口投与するための方法及び組成物

Country Status (18)

Country Link
EP (1) EP1225956A1 (zh)
JP (1) JP2003512443A (zh)
KR (1) KR20030019296A (zh)
CN (1) CN1450923A (zh)
AU (1) AU1104201A (zh)
BR (1) BR0015149A (zh)
CA (1) CA2389583A1 (zh)
CO (1) CO5251425A1 (zh)
CZ (1) CZ20021484A3 (zh)
HU (1) HUP0203303A3 (zh)
IL (1) IL149360A0 (zh)
MX (1) MXPA02004164A (zh)
NO (1) NO20022008L (zh)
PL (1) PL354777A1 (zh)
RU (1) RU2002113659A (zh)
SK (1) SK5822002A3 (zh)
WO (1) WO2001030448A1 (zh)
ZA (1) ZA200203358B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508340A (ja) * 2004-08-03 2008-03-21 ノバルティス アクチエンゲゼルシャフト レニン阻害剤のバイオアベイラビリティーの改善法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
WO2002043765A2 (en) 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
US9402812B2 (en) 2009-09-23 2016-08-02 Indu JAVERI Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
MX341082B (es) 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4308114A1 (en) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU756752B2 (en) * 1998-04-01 2003-01-23 Skyepharma Canada Inc. Anticancer compositions
AU784416B2 (en) * 1999-05-21 2006-03-30 Abraxis Bioscience, Llc Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508340A (ja) * 2004-08-03 2008-03-21 ノバルティス アクチエンゲゼルシャフト レニン阻害剤のバイオアベイラビリティーの改善法

Also Published As

Publication number Publication date
KR20030019296A (ko) 2003-03-06
CA2389583A1 (en) 2001-05-03
PL354777A1 (en) 2004-02-23
NO20022008L (no) 2002-06-19
ZA200203358B (en) 2003-04-29
CZ20021484A3 (cs) 2003-12-17
HUP0203303A3 (en) 2005-01-28
IL149360A0 (en) 2002-11-10
WO2001030448A1 (en) 2001-05-03
RU2002113659A (ru) 2004-01-27
CO5251425A1 (es) 2003-02-28
MXPA02004164A (es) 2002-10-17
NO20022008D0 (no) 2002-04-26
CN1450923A (zh) 2003-10-22
EP1225956A1 (en) 2002-07-31
BR0015149A (pt) 2002-10-29
HUP0203303A2 (hu) 2003-02-28
AU1104201A (en) 2001-05-08
SK5822002A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
JP3361102B2 (ja) 医薬の経口生体利用率を増加させるための方法、組成物およびキット
US5968972A (en) Method for increasing the oral bioactivity of pharmaceutical agents
JP2003512443A (ja) タキサンをヒト患者に経口投与するための方法及び組成物
US8541433B2 (en) Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
KR100615783B1 (ko) 탁산 치료를 받고 있는 인체를 제외한 포유동물의 과민증 또는 알러지 반응을 경감시키기 위한 방법 및 약학적 키트
EP1634607A2 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR100563824B1 (ko) 제약학적약물의경구생체내이용효율을증가시키기위한조성물및키트